Corgenix Med Corp (CONX) 0.2580 $CONX
Corgenix Signs Memorandum of Understanding Regarding Settlement of Litigation and Announces Plan to Adjourn Special Meeting to December 10
Business Wire - Wed Nov 19, 4:09PM CST
Corgenix Medical Corporation (OTCQB: CONX.OB) (the "Company"
announced today that it has entered into a memorandum of understanding with plaintiffs' counsel in the consolidated Nevada putative shareholder class action lawsuit described in the Company's definitive proxy statement dated October 21, 2014, as supplemented (the "Proxy Statement" , in connection with the Company's proposed merger with an affiliate of Orgentec Diagnostika (the "Merger" .
Corgenix down to Q1 2014 net loss of USD770,000
M2 - Thu Oct 30, 6:02AM CDT
Diagnostic test company Corgenix Medical (Other OTC:CONX) announced on Wednesday its net loss of USD770,000 for the first quarter ended 30 September 2014.
Corgenix Announces Preliminary Revenue and Net Loss Results for Quarter ended September 30, 2014
Business Wire - Wed Oct 29, 8:35AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today reported preliminary revenue results for the first quarter (ended September 30, 2014), which came in at approximately $2.2 million versus approximately $2.9 million for the same quarter in the previous year. In addition, due to the lower revenues and the expenses related to the pending strategic merger with Orgentec Diagnostika, the Company incurred a net loss for the period of approximately $770,000 versus net income of approximately $84,000 for the same quarter in the previous year.
Corgenix Medical Corporation Stockholders Encouraged to Contact Securities Law Firm about the definitive merger agreement to be acquired by Orgentec Diagnostika
PR Newswire - Wed Sep 03, 4:52PM CDT
Securities lawyers at Dunnam & Dunnam are investigating potential claims against the Board of Directors of Corgenix Medical Corporation (OTC:CONX) in connection with the definitive merger agreement of Corgenix Medical to Orgentec Diagnostika. Concerned CONX investors are encouraged to contact attorney Hamilton Lindley by clicking here.
Corgenix to be acquired by Orgentec Diagnostika in USD16m transaction
M2 - Fri Aug 29, 6:32AM CDT
Corgenix Medical Corporation (OTCQB:CONX.OB), a developer and marketer of diagnostic test kits, announced on Thursday the entering into a definitive merger agreement to be acquired by Orgentec Diagnostika, a specialty diagnostics company headquartered in Mainz, Germany.
Corgenix Provides Update on Ebola Test Kit NIH Grant
Business Wire - Mon Aug 11, 8:15AM CDT
Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year's outbreak is the worst in recorded history, with the total number of deaths approaching 1,000. As reported previously, Corgenix Medical Corporation (OTCBB:CONX), a worldwide developer and marketer of diagnostic test kits, commenced work on a $2.9 million National Institutes of Health (NIH) grant in June.
Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Business Wire - Wed Jul 30, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection," presented at the conference by Corgenix Research Associate Abby Jones, M.S.
Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Business Wire - Tue Jul 22, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.
Corgenix enters into technology transfer & product development agreement for Mellitussfor gestational diabetes test GCD59
M2 - Tue Jul 15, 8:29AM CDT
Diagnostic test kits company Corgenix Medical (Other OTC:CONX) on Monday launched a technology transfer and product development agreement with Mellitus in support of clinical research and product commercialisation.
Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Business Wire - Mon Jul 14, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Business Wire - Thu Jun 26, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.
Corgenix Signs Memorandum of Understanding Regarding Settlement of Litigation and Announces Plan to Adjourn Special Meeting to December 10
Business Wire - Wed Nov 19, 4:09PM CST
Corgenix Medical Corporation (OTCQB: CONX.OB) (the "Company"
announced today that it has entered into a memorandum of understanding with plaintiffs' counsel in the consolidated Nevada putative shareholder class action lawsuit described in the Company's definitive proxy statement dated October 21, 2014, as supplemented (the "Proxy Statement" , in connection with the Company's proposed merger with an affiliate of Orgentec Diagnostika (the "Merger" . Corgenix down to Q1 2014 net loss of USD770,000
M2 - Thu Oct 30, 6:02AM CDT
Diagnostic test company Corgenix Medical (Other OTC:CONX) announced on Wednesday its net loss of USD770,000 for the first quarter ended 30 September 2014.
Corgenix Announces Preliminary Revenue and Net Loss Results for Quarter ended September 30, 2014
Business Wire - Wed Oct 29, 8:35AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today reported preliminary revenue results for the first quarter (ended September 30, 2014), which came in at approximately $2.2 million versus approximately $2.9 million for the same quarter in the previous year. In addition, due to the lower revenues and the expenses related to the pending strategic merger with Orgentec Diagnostika, the Company incurred a net loss for the period of approximately $770,000 versus net income of approximately $84,000 for the same quarter in the previous year.
Corgenix Medical Corporation Stockholders Encouraged to Contact Securities Law Firm about the definitive merger agreement to be acquired by Orgentec Diagnostika
PR Newswire - Wed Sep 03, 4:52PM CDT
Securities lawyers at Dunnam & Dunnam are investigating potential claims against the Board of Directors of Corgenix Medical Corporation (OTC:CONX) in connection with the definitive merger agreement of Corgenix Medical to Orgentec Diagnostika. Concerned CONX investors are encouraged to contact attorney Hamilton Lindley by clicking here.
Corgenix to be acquired by Orgentec Diagnostika in USD16m transaction
M2 - Fri Aug 29, 6:32AM CDT
Corgenix Medical Corporation (OTCQB:CONX.OB), a developer and marketer of diagnostic test kits, announced on Thursday the entering into a definitive merger agreement to be acquired by Orgentec Diagnostika, a specialty diagnostics company headquartered in Mainz, Germany.
Corgenix Provides Update on Ebola Test Kit NIH Grant
Business Wire - Mon Aug 11, 8:15AM CDT
Ebola virus outbreaks tend to occur every few years and then go away rapidly. However, this year's outbreak is the worst in recorded history, with the total number of deaths approaching 1,000. As reported previously, Corgenix Medical Corporation (OTCBB:CONX), a worldwide developer and marketer of diagnostic test kits, commenced work on a $2.9 million National Institutes of Health (NIH) grant in June.
Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Business Wire - Wed Jul 30, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection," presented at the conference by Corgenix Research Associate Abby Jones, M.S.
Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Business Wire - Tue Jul 22, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.
Corgenix enters into technology transfer & product development agreement for Mellitussfor gestational diabetes test GCD59
M2 - Tue Jul 15, 8:29AM CDT
Diagnostic test kits company Corgenix Medical (Other OTC:CONX) on Monday launched a technology transfer and product development agreement with Mellitus in support of clinical research and product commercialisation.
Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Business Wire - Mon Jul 14, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Business Wire - Thu Jun 26, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.
